The review makes various recommendations including the creation of a new accelerated access partnership to speed up and simplify the process for getting the most promising new treatments and diagnostics safely from pre-clinical development to patients. Through the new partnership, innovators would be able to access joined-up help for clinical development, regulation, and assessment of cost effectiveness. It is recommended that the partnership includes NHS England, NHS Improvement, the National Institute for Health and Care Excellence (NICE) and the Medicines and Healthcare Products Regulatory Agency (MHRA).
Patient access to drugs could be brought forward by up to 4 years if a scientific opinion from the early access to medicines scheme is used (saving 12 to 18 months) and there is no delay during the technology appraisal (which takes around 2 years) or during the process for NHS commissioning and adoption (which takes 2 years or more).